Fresh Tracks Therapeutics Fresh Tracks Therapeutics Home
  • Company
    • Vision
    • Values
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partner With Us
    • Join Us
  • Scientific Innovations
  • Pipeline
    • Overview
    • FRTX-02
    • FRTX-10
    • Next-Generation Kinase Inhibitors
    • FRTX-03
  • Investor Relations
Main Menu
Contact Us
Investor Relations

News

Investors

Investors

  • Overview
  • News
  • Events
  • Presentations
  • Governance
    • Leadership
    • Board of Directors
    • Board Committees
    • Governance Documents
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
Feb 20, 2020 6:30am EST

Brickell Biotech Announces Publication of its U.S. Phase 2b Study Results for Sofpironium Bromide in Patients with Primary Axillary Hyperhidrosis in the Journal of the American Academy of Dermatology

Feb 18, 2020 6:30am EST

Brickell Biotech Announces Settlement of Dispute with Bodor Labs and Entry into Equity Funding Agreements

Jan 10, 2020 4:05pm EST

Brickell Bio’s Development Partner, Kaken Pharmaceutical, Submits New Drug Application for Sofpironium Bromide in Japan for Primary Axillary Hyperhidrosis

Nov 13, 2019 4:05pm EST

Brickell Bio Announces Third Quarter 2019 Financial Results and Provides Corporate Update

Oct 30, 2019 4:42pm EDT

Brickell Biotech Provides Update on Bodor Labs Complaint and Funding Agreement with NovaQuest

Sep 03, 2019 6:00am EDT

Brickell Biotech Completes Merger with Vical

Jun 03, 2019 3:00am EDT

Vical and Brickell Announce Merger Agreement

Nov 19, 2018 9:00am EST

Brickell Biotech Appoints Top Lilly Executive, Robert Brown, as Chief Executive Officer

Feb 20, 2018 8:00am EST

Sofpironium Bromide Demonstrates Promising Potential as a Safe and Effective First-Line Treatment for Primary Axillary Hyperhidrosis (Excessive Underarm Sweating)

Oct 24, 2017 8:00am EDT

Brickell Biotech Announces Positive Phase 2b Study Results for BBI-4000 (Sofpironium Bromide) in Subjects with Primary Axillary Hyperhidrosis

  • Previous Pagearrow_back
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Next Pagearrow_forward
  • Email Alerts
  • RSS News Feed

Company

  • Vision
  • Values
  • Leadership
  • Partner With Us
  • Join Us

Discover

  • Scientific Innovations
  • Pipeline
  • Investor Relations
  • News
  • Contact Us

Follow Us

  • LinkedIn
  • Twitter
  • Instagram
  • Facebook
  • Compliance
  • Terms of Use
  • Privacy Policy
  • Accessibility
©2023 Fresh Tracks Therapeutics, Inc.

We use first- and third-party cookies to obtain statistical information to personalize our website and provide you with a better experience. If you continue without changing your settings, this demonstrates your consent to receive all cookies or other tracking technologies on the FRTX website for the purposes described in our Privacy Policy. Please know that you can change your cookie settings at any time in your browser settings.

Close